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NeuroinﬂammationisinvolvedinthepathogenesisofAlzheimer’sdisease(AD).Microglia,macrophage-likeresidentimmunecells
in the brain, play critical roles in the inﬂammatory aspects of AD. Microglia may be activated by oligomeric and ﬁbrillar species of
amyloid β (Aβ) that are constituents of senile plaques and by molecules derived from degenerated neurons, such as purines and
chemokines, which enhance their migration and phagocytosis. The main neurotoxic molecules produced by activated microglia
may be reactive oxygen species, glutamate, and inﬂammatory cytokines such as tumor-necrosis-factor-α and interleukin- (IL-) 1β
These molecules diﬀerentially induce neurotoxicity. Aβ itself directly damages neurons. In terms of neuroprotective properties,
microglia treated with fractalkine or IL-34 attenuate Aβ neurotoxicity by Aβ clearance and the production of antioxidants. There-
fore, regulation of the microglial role in neuroprotection may be a useful therapeutic strategy for AD.
1.Introduction
Microglia, macrophage-like immune cells in the central ner-
vous system (CNS), cluster around the senile plaques that
along with polymorphous amyloid β (Aβ)d e p o s i t sa r e
the pathological hallmarks of Alzheimer’s disease (AD).
Microglia have a biphasic neurotoxic-neuroprotective role in
the pathogenesis of AD. In regard to their neurotoxic proper-
ties, microglia may be involved in the inﬂammatory compo-
nent of AD [1, 2]. In AD, the trigger molecule for microglial
activation may be Aβ and molecules derived from degene-
rated neurons may enhance microglial neurotoxicity [3]. Aβ
exists in diﬀerent assembly forms including monomers, oli-
gomers, and ﬁbrils. Both oligomeric Aβ (oAβ)a n dﬁ b r i l l a r
Aβ (fAβ) have been shown to stimulate microglial secre-
tion of proinﬂammatory cytokines such as interleukin-1
(IL-1), IL-6, and tumor-necrosis-factor-α (TNF-α); chemo-
kines including monocyte chemotactic-1 (MCP-1) and
macrophage inﬂammatory protein-1 (MIP-1); complement
c o m p o n e n t s ;f r e er a d i c a l ss u c ha sr e a c t i v eo x y g e ns p e c i e s
(ROS), including superoxide anions and hydroxy radicals [4,
5]. Glutamate also plays an important role in microglial
neurotoxicity in AD. Activated microglia produce large
amounts of glutamate, which induces excitotoxicity via
N-methyl-D-aspartate (NMDA) receptor signaling [6–9].
Chronic activation of extrasynaptic NMDA receptors leads
to increased Aβ production [10].
Aβ itself is toxic to neurons in AD, with oAβ being more
toxic than fAβ (Figure 1). The toxicity of oAβ manifests itself
intermsofsynapticdysfunction,includinginhibitionofhip-
pocampal long-term potentiation, facilitation of long-term
depression,anddisruptionofsynapticplasticity[11,12].Itis
thereforenecessarytoevaluatemicroglialneurotoxicityapart
from Aβ neurotoxicity.
In regard to its neuroprotective properties, microglia at-
tenuate Aβ neurotoxicity by Aβ clearance, including phago-
cytosis and degradation of Aβ and the production of antioxi-
dantsandneurotrophicfactors[13–15].Inthepresentpaper,
we focus on the trigger molecules that mediate microglial
activation and the mechanisms of microglial neurotoxicity
mediated by ROS glutamate, and inﬂammatory cytokines.
We also discuss the neuroprotective role of microglia in AD.
2. The Trigger Molecules That
MediateMicroglialActivation
2.1. Fibrillar Aβ. Aβ, the key mediator of AD, is processed
from the amyloid precursor protein (APP). The most
common isoforms are Aβ1-40 and Aβ1-42, which are the2 International Journal of Alzheimer’s Disease
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Figure 1: Aβ neurotoxicity. Aβ is derived from APP by enzymatic cleavage. Aβ consists of 40 or 42 amino acids. Aβ40 is soluble and of lower
toxicity, but Aβ42 is prone to aggregate and form ﬁbrillar structures via oligomers (a). Oligomeric Aβ (oAβ42) and ﬁbrillar Aβ (fAβ42) are
detected by western blotting and an electron microscope (b). Administration of 5μMo A β42 to cortical cultures induces signiﬁcant neuronal
death. In contrast, administration of fAβ42 does not induce neuronal cell death, although Aβ deposition is observed on dendrites (c).
major constituents of senile plaques. Aβ1-42 is more prone
to aggregate than Aβ1-40. Initial Aβ deposition begins with
Aβ1-42, but not with Aβ1-40. In the process of Aβ1-42
aggregation, many types of soluble oAβ are formed: dimers,
trimers, tetramers, dodecamers, Aβ-derived diﬀusible lig-
ands, and annular protoﬁbrils [16–18]. Stimulation of mic-
roglia with fAβ reportedly results in the Syk kinase- and
NFκB-dependent production of TNF-α,i N O S ,a n dp e r o x -
ynitrite[19].However,theabilityoffAβ toactivatemicroglia
is generally low or absent when fAβ is used as the sole sti-
mulant. Recent reports have clariﬁed that fAβ can activate
microglia via Toll-like receptor 2 (TLR2) [20] or interaction
with cell surface receptor complexes. TLR2, TLR4, and TLR6
have been shown to be essential components of the receptor
complexes for microglial activation. The coreceptor CD14
and TLR2 and 4 complex is required for fAβ-stimulated mic-
roglial activation [21]. The class B scavenger receptor CD36
and TLR4 and 6 complex is also involved in the activation of
microglia by fAβ. The signals mediated by this receptor com-
plex induce IL-1β production in microglia [22].
2.2. Oligomeric Aβ. The patterns of microglial activation
caused by fAβ and oAβ are diﬀerent. In addition, studies of
microglial activation with oAβ have yielded controversial
results. oAβ activates microglia by increasing levels of phos-
phorylated Lyn, Syk kinase, and p38 MAP kinase, which
results in the production of IL-6 and a decrease in MCP-1
[23].Ontheotherhand,oAβdoesnotproduceseveralproin-
ﬂammatory mediators commonly induced by lipopolysac-
charides (LPS), such as prostaglandin E2, glutamate, TNF-α,
IL-1β, and IL-6. There is a report that oAβ at low nanomolar
concentrations induces neurotoxicity by increasing the pro-
duction of nitric oxide (NO) as well as the activity of scaven-
ger receptor A and the Ca2+-activated potassium channel
KCa3.1 [24]. oAβ induces neuronal ROS through a mecha-
nism requiring NMDA receptor activation [25]. ROS is also
induced by fAβ and oAβ in microglia [26]. In contrast to the
above reports, our data showed that both fAβ and oAβ failed
t oi n d u c et o x i cm o l e c u l e ss u c ha sT N F - α,N O ,a n dgl u t a m a t e
inmicrogliaandtoenhancethesemoleculesinLPS-activated
microglia (Figure 2)[ 15]. The synthetic oAβ that is usedInternational Journal of Alzheimer’s Disease 3
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Figure 2: Inﬂammatory molecules produced by Aβ- or LPS-activated microglia. In primary microglial culture, administration of 5μM
oAβ42 or 5μMf A β42 for 24h does not induce the production of neurotoxic mediators such as TNF-α, glutamate, or nitrite, a stable
breakdown product of NO. While microglia activated with 1μg/mL LPS produce these molecules, both oAβ42 and fAβ42 do not enhance
the production.
for in vitro studies contains oligomers of diﬀerent sizes and
shapes, and microglia may respond to this heterogeneous
oAβ mixture in various ways. Moreover, synthetic oAβ pre-
parations are less potent than oAβ isolated from the super-
natant of transfected cell cultures.
2.3. The Molecules Derived from Degenerated Neurons.
Recentﬁndingshaveindicatedthatdamagedneuronsarenot
merely passive targets of microglia but rather regulate mic-
roglial activity through nucleotides and chemokines [27].
Damaged neurons release several substances that activate
microglia,forinstancepurines,including ATP[28]andUDP
[29]; chemokines, such as CCL-21 [30]; glutamate [31].
However, these molecules do not always induce microglial
neurotoxicity.ATPregulatesmicroglialbranchdynamicsand
mediates a rapid microglial response toward injured neu-
rons. UDP triggers microglial phagocytosis via P2Y6 recep-
tors. The chemokine CCL-21, released by damaged neurons,
activates microglia via the CXCR3 receptor. Excessive neu-
ronal glutamate is released as a result of neurodegenerative
processes. Microglial cells express the AMPA and kainate
subtypes of ionotropic glutamate receptors [32]. Metabot-
ropic glutamate (mGlu) receptor 2, mGlu3, and mGlu5 are
expressed in microglia [33, 34] .G l u t a m a t es e r v e sa sa n
activation signal for microglia, and activation of mGluR2
on microglia promotes neurotoxicity. However, microglial
mGluR5 provides neuronal protection by suppressing the
NO and TNF-α production induced by blood protein ﬁbri-
nogen [34].
3.TheNeurotoxicMoleculesProduced
byMicroglia
3.1. ROS. Oxidative damage to protein, lipids, polysaccha-
rides, and DNA is involved in the pathogenesis of AD
[35]. The expression of NADPH oxidase, a multisubunit
enzyme complex responsible for the production of ROS, is
upregulated in AD [36]. Microglial NADPH oxidase is acti-
vated by fAβ [37, 38], and NADPH oxidase activation sub-
sequently causes neurotoxicity through two mechanisms: (1)
extracellular ROS produced by microglia are directly toxic to
neurons, and (2) intracellular ROS function as a signaling
mechanism in microglia to amplify the production of several
proinﬂammatory and neurotoxic cytokines [39]. ROS are in-
duced in the mitochondrial membranes of both neurons
and microglia, causing subsequent oxidative damage in the
early stages of disease progression. Loss of mitochondrial
membrane potential and increase of ROS production have
been demonstrated in studies of AD patients as well as in
transgenicmicemodelsofAD[40,41].Anincreaseinhydro-
gen peroxide and a decrease in cytochrome oxidase activity
were found in young Tg2576 mice prior to the appearance
of Aβ plaques [40]. Oxidative stress has been shown to
contribute to the onset of cognitive dysfunction caused by
Aβ [42].
A recent report showed that fAβ and oAβ induced ROS
in microglia through the TRPV1 cation channel, also known
as the capsaisin receptor, and that pretreatment with fAβ
or oAβ induced microglial priming through Kv1.3K(+)
channels, that is, increased ROS production upon secondary
stimulation with the phorbol ester PMA [26]. The translo-
cation of chloride intracellular channel 1 from the cytosol
to the plasma membrane is also involved in microglial ROS
generation [43].
Neuronal ROS induced by Aβ can be selectively dysfunc-
tional as well as degenerative. Overstimulation of excitatory
NMDA receptors can lead to excessive ROS. Antioxidative
enzyme heme oxygenase-1 (HO-1) is a microsomal enzyme
that oxidatively cleaves heme to produce biliverdin, carbon
monoxide, and iron [44]. Aβ binds to heme to promote a
functional heme deﬁciency and induces mitochondrial dys-
function and neurotoxicity [45]. APP also binds to HO, and
oxidative neurotoxicity is markedly enhanced in cerebral4 International Journal of Alzheimer’s Disease
cortical cultures from APP Swedish mutant transgenic mice
[46].
3.2. Glutamate. Activated microglia release large amounts of
glutamate through upregulation of glutaminase expression
and induce excitoneurotoxicity through NMDA receptor
signaling [7, 47, 48]. Microglial glutamate production is
reported to be induced by APP, but not Aβ [48]. Excessive
glutamate increases Ca2+ inﬂux via the NMDA recep-
tor, resulting in Ca2+/calmodulin-dependent protein kinase
(CaMK) activation. NO induced by CaMK inhibits mito-
chondrialfunction.StimulationofsynapticNMDAreceptors
enhances prosurvival signals through the activation of
cAMP response element-binding protein (CREB) and the
extracellular signal-regulated kinase (ERK) cascade [49, 50],
whereas calcium ﬂux through extrasynaptic NMDA recep-
tors overrides these functions, causing mitochondrial dys-
function and neuronal cell death [51, 52]. A recent report
suggested that chronic activation of extrasynaptic NMDA
receptors leads to sustained neuronal Aβ release via amy-
loidogenic APP expression [53].
Focalbead-likeswellingindendritesandaxons,knownas
neuritic beading, is a neuropathological sign that is a feature
of neuronal cell dysfunction preceding neuronal death in
various diseases such as ischemia, epilepsy, brain tumor, and
AD [54–57]. We found that glutamate from activated mic-
roglia induces neuritic beading by impairing dendritic and
axonal transport through NMDA receptor signaling [7].
Moreover, we demonstrated that gap junction hemichannels
are the main avenue of excessive glutamate release from neu-
rotoxic activated microglia [6] .T h eb l o c k a d eo fg a pj u n c t i o n
hemichannels by glycyrrhetinic acid derivatives signiﬁcantly
prevents activated microglia-mediated neuronal death in
vitro [7, 58, 59] and in vivo in rodent models of transient
ischemic brain injury, multiple sclerosis, amyotrophic lateral
sclerosis, and AD [60–62]. In the APP/PS1 transgenic mouse
model of AD, glycyrrhetinic acid derivatives improved mem-
ory impairments without altering Aβ deposition [62].
oAβ is directly neurotoxic as a result of inducing gluta-
mate release from hippocampal neurons and may contribute
to dysregulation of excitatory signaling in neurons [63].
3.3. Inﬂammatory Cytokines. oAβ,b u tn o tf A β,h a sb e e n
shown to increase levels of TNF-α and IL-1β in rat microglial
cultures [64]. However, gene expression analysis of microglia
using cDNA arrays has conﬁrmed that the upregulation of
TNF-αandIL-1β iscausedbybothoAβ andfAβ [65].TNF-α
is a well-characterized proinﬂammatory cytokine involved in
manyneuroinﬂammatorycascades,includingautocrineacti-
vationofmicroglia[66]anddirectapoptosisviaactivationof
extrinsic pathway-associated TNF receptors [67, 68]. TNF-α
enhances microglial glutaminase expression, glutamate pro-
duction, and cell-surface expression of gap junction hemi-
channels [6]. Synergistic and autocrine activities of TNF-α
may cause the release of large amounts of glutamate, result-
ing in excitotoxic neuronal death [69]. TNF-α has been
shown to directly upregulate the expression of the AMPA
receptor GluR1 subunit in mouse hippocampus and cerebral
cortex neurons [70] and to exacerbate AMPA-induced neu-
ronal death at high doses [71]. TNF-α has also been reported
to enhance excitotoxicity through synergistic stimulation of
the TNF and NMDA receptors [72].
IL-1β is known to be a driving force in the inﬂammatory
process in AD, and it promotes the synthesis and processing
of APP [73]. IL-1β aﬀects ion currents, intracellular Ca2+
homeostasis, and membrane potentials and suppresses long-
term potentiation, thus contributing to dysfunction and in-
ﬂammation [74]. A recent report indicated that the cytoplas-
mic receptor NALP3 inﬂammasome is involved in the innate
immune response in AD [75]. Activation of the microglial
NALP3 inﬂammasome is initiated by phagocytosis of fAβ
and induces lysosomal damage and cathepsin B release.
Moreover, it leads to the cleavage of pro-IL-1β/pro-IL-18
into IL-1β/IL-18 by caspase-1. Subsequently, IL-1β activates
the secretion of several proinﬂammatory and chemotactic
mediators [75].
Wnt signaling plays an important role in neural devel-
opment, including synaptic diﬀerentiation. Wnt 5a and its
receptor Frizzled-5 have been shown to be upregulated in
the AD mouse brain [76], and activation of Wnt5a signaling
enhances Aβ-evoked neurotoxicity by induced TNF-α and
IL-1β [76]. In contrast, postsynaptic damage induced by
oAβ in hippocampal neurons is reported to be prevented by
Wnt5a [77]. This discrepancy can be explained by the fact
that basal Wnt5a has synaptoprotective activity, but excessive
Wnt5a may induce proinﬂammatory factors.
4. Phagocytosis of Microglia
Microglial phagocytosis of neuronal debris and Aβ plays a
pivotal role in AD. Phagocytosis is associated with inﬂam-
mationduringuptakeofmicrobesviaTLRsandFcreceptors,
while phagocytosis of apoptotic cells is executed with-
out inﬂammation via phosphatidylserine receptors such as
T-cell-immunoglobulin-mucin-4 (TIM-4) [78, 79]. Milk-
fat-globule-EGF-factor-8 (MFG-E8), secreted by activated
microglia or macrophages, also binds to phosphatidylserine
exposed on plasma membranes of apoptotic cells [80, 81].
Phagocytosis with inﬂammation may be toxic to neurons
becauseoftheproductionofinﬂammatorymoleculessuchas
proinﬂammatory cytokines, NO, and ROS. However, phago-
cytosis of Aβ contributes to microglial neuroprotection in
AD.Peptidoglycan,theTLR2ligand,andunmethylatedDNA
CpG motifs, the TLR9 ligand, increase Aβ phagocytosis
through protein-coupled formyl peptide receptor-like 2 [82,
83]. Similarly, LPS, the TLR4 ligand, increases phagocytosis
through the CD14 receptor [84]. TLR4 mutation exacerbates
the Aβ b u r d e ni nm o u s em o d e l so fA D[ 85].
5. Molecules Able to InduceMicroglial
Neuroprotective Properties
5.1. Fractalkine. Degenerating neurons produce signaling
molecules that regulate microglial phagocytosis and neuro-
protection. Some of this signaling may be controlled by
chemokines and chemokine receptors, which are widelyInternational Journal of Alzheimer’s Disease 5
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Figure 3: Aβ toxicity in neurons and microglia. Aβ is directly toxic to neurons by ROS, and enhances the production of microglia-derived
neurotoxic molecules such as glutamate, TNF-α,a n dI L - 1 β. Glutamate from degenerated neurons also induces microglial neurotoxicity.
IL-34 and FKN induce microglial neuroprotection via Aβ clearance and antioxidant activity.
expressed throughout the central nervous system [86]. We
have shown that the soluble CX3C chemokine fractalkine
(FKN), secreted from damaged neurons, promotes mic-
roglialphagocytosisofneuronaldebristhroughthereleaseof
MFG-E8 and induces the expression of the antioxidant
enzyme HO-1 in microglia, resulting in neuroprotection
against glutamate toxicity [87]. The end-products of HO-1
including biliverdin, carbon monoxide, and iron provide cel-
lular and tissue protection through antiinﬂammatory, anti-
apoptotic, or antioxidative eﬀects [88]. Numerous studies
have demonstrated that upregulation of HO-1 expression in
the CNS may be beneﬁcial to counteract neuroinﬂammation
and neurodegenerative diseases [89]. The neuroprotective
eﬀect of FKN is abolished by treatment with the HO-1 inhi-
bitor tin-mesoporphyrin IX (SnMP). Moreover, FKN sup-
presses microglial NO, IL-6, and TNF-α production [90].
FKNsignalingisdeﬁcientinADbrainsandisdownregulated
by Aβ. CX3CR1, the fractalkine receptor, is a key member
of the microglial pathway that protects against AD-related
cognitive deﬁcits that are associated with aberrant microglial
activation and elevated inﬂammatory cytokines [91]. Mice
lacking the CX3CR1 receptor show cognitive dysfunction as
demonstrated by contextual fear conditioning and Morris
water maze tests, deﬁcits in motor learning, and a signiﬁcant
impairment in long-term potentiation via increase in IL-1β
[92]. CX3CR1 deﬁciency worsens the AD-related neuronal
and behavioral deﬁcits [91]. In contrast, CX3CR1 deﬁciency
is reported to reduce Aβ deposition in AD mouse models
[93]. Thus, FKN-CX3CR1 signaling in AD is still controver-
sial.
5.2. IL-34. The dimeric glycoprotein IL-34, which is mainly
expressed in neurons, may also be a neuronal cytokine that
regulates microglial function. The major function of IL-34
is to stimulate the diﬀerentiation and proliferation of mono-
cytes and macrophages via the colony-stimulating-factor-
(CSF-) 1 receptor [94]. We have shown that IL-34 induces
microglial proliferation and antioxidant HO-1 production
and enhances the degradation of Aβ via insulin degrading
enzyme (IDE) (also known as Aβ degrading enzyme) and
that IL-34 reduces the amount of oAβ and ROS present in
the supernatant of neuron-microglia cocultures, resulting in
microglial neuroprotection against oAβ toxicity [95]. IDE
activity is critical in determining the level of Aβ. The levels
of hippocampal IDE protein and activity have been shown to
be reduced in AD [96]. Enhanced IDE activity in IDE/APP
double-transgenic mice decreased Aβ levels and prevented
the development of AD pathology [97]. Moreover, single
intracerebroventricularinjectionofIL-34eﬀectivelysuppres-
sed the impairment of associative learning in an APP/PS1
transgenic mouse model of AD [95]. The injection of IL-34
may act directly on microglia, which can rapidly eliminate
oAβ via upregulation of IDE and exert antioxidant eﬀect via
HO-1.
5.3. M-CSF. CSF-1, also known as macrophage colony-
stimulating factor (M-CSF), is another ligand of the CSF-1
receptor. M-CSF enables the acidiﬁcation of macrophage
lysosomes and subsequently the degradation of internalized
Aβ [98]. Intraperitoneal injection of M-CSF prevents mem-
ory disturbance in APP/PS1 mice by inducing microglial
phagocytosis of Aβ [99]. A recent report showed that IL-34
and M-CSF diﬀer in their structure and the CSF-1 receptor
domains that they bind, causing diﬀerent bioactivities and
signal activation kinetics [100]. Both IL-34 and M-CSF are
useful molecules in terms of inducing microglial neuropro-
tective properties.
5.4. CpG. TLR9, which is located in the intracellular endo-
somal-lysosomal compartment in innate immune cells,
detects single-stranded DNA containing unmethylated CpG.
Microglia express TLR9 at higher levels than do astrocytes
and neuronal cells. Thus, CpG mainly acts on microglia in
the CNS. We have also shown that microglia activated by6 International Journal of Alzheimer’s Disease
CpG attenuate oAβ neurotoxicity [15]. While high concen-
trations of CpG (10μM) induce TNF-α, IL-12, and NO in
microglia and enhance neuronal damage [101, 102], lower
concentrations of CpG (1nM–100nM) enhance microglial
phagocytosis of Aβ without inﬂammation. Intracerebroven-
tricular administration of CpG ameliorates both the cogni-
tive impairments induced by oAβ and the impairment of
associative learning in a Tg2576 mouse model of AD [15].
Taken together, these molecules induce neuroprotective
propertiesinmicrogliathroughtheantioxidanteﬀectofHO-
1andAβclearance.HO-1isinducedbynucleartranslocation
of Nrf2, which is a transcription factorand reportedly plays a
pivotal role in cellular survival [103, 104]. Nrf2 gene therapy
alsohasbeenshowntoimprovememoryinthemousemodel
of AD [105]. Moreover, Aβ clearance including phagocytosis
and degradation of Aβ by microglia can decrease Aβ plaque
formation and Aβ toxicity.
6. Conclusion
While Aβ, especially oAβ, is directly toxic to neurons, it
may also enhance microglial neurotoxic eﬀects by induc-
ing inﬂammatory mediators. Degenerated neurons produce
molecules other than Aβ that enhance microglial neurotoxi-
city. However, the microglial neuroprotective eﬀect resulting
from Aβ clearance and antioxidant activity is obvious in AD
(Figure 3). The conditions that determine microglial toxic or
protective eﬀects remain to be elucidated. Clarifying these
issues may contribute to the understanding of AD patho-
physiology. A useful therapeutic strategy for AD may be to
regulate microglia toward neuroprotection, speciﬁcally, Aβ
clearance without inﬂammation.
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